Ventrus falls after stopping iferanserin development

Ventrus Biosciences Inc. (NASDAQ:VTUS) fell $7.24 (59%) to $5.02 on Monday after discontinuing development of topical iferanserin after it missed the primary endpoint in a Phase III trial to treat hemorrhoids. Both 7- and 14-day treatment regimens of twice-daily iferanserin ( VEN 309) did not significantly improve the proportion of patients with cessation of bleeding at day seven that persists through day 14 vs. placebo. The trial enrolled 603 patients. Iferanserin is a selective serotonin (5-HT2) receptor antagonist. ...